13 research outputs found
Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue
Aim: To study the efficacy of autovaccine in the treatment of gastric cancer and significance of molecular factors having prognostic values for disease outcome to evaluate its efficacy in clinical setting. Patients and Methods: 150 patients with histologically proven adenocarcinoma of the stomach of stages II, III or IV were enrolled into study. 86 patients have been treated with autovaccine (AV) after operation. Expression of p53, Bcl-2, receptors of tyrosine kinase, vascular endothelial growth factor (VEGF), Π-cadherin, Ξ±-catenin and Ξ²-catenin was determined in paraffin embedded tumor samples by means of immunohistochemical method with the use of respective monoclonal antibodies. Results: It was shown that application of AV has resulted in the increase of 3-year overall survival of patients having stage III of disease by more than 30%, but those having stage IV β only around 14%. The increase of 3-year overall survival of patients with metastases in lymph nodes (N1β2) was observed also in more than 30%. It has been suggested the optimal phenotype for vaccine application: Ρ53(+), EGFR(+), HER-2 neu (+), Ξ²-catenin (+), VEGF(+) and Bcl-2(+) with no dependence on E-cadherin and Ξ±-catenin presence. Conclusion: It was determined that the best effect of AV application is observed in patients with category Π’3β4, poorly-differentiated tumors, metastases in lymph nodes (N1β2), but without distant metastases (Π0). Gastric cancer patients with p53, EGFR, HER-2/neu, Ξ²-catenin, VEGF and Bcl-2-positive tumors are the favorable group for the treatment with AV in the adjuvant regime
Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
The aim of this paper is to study preventive effect of cytotoxic lectin from Bacillus subtilis B-7025 on the tumor growth and nonspecific immunity in sarcoma 37 transplanted mice
Influence of teichoic acid from S. Aureus on metabolic activity of macrophages and cytotoxic activity of splenocytes of mice bearing Lewis lung carcinoma
To investigate the effect of teichoic acid (TA) from the cell wall of S. aureus on some indices of immunological reactivity in mice bearing Lewis lung carcinoma (LLC). Methods: The teichoic acid at the doses of 1, 2 and 4 Β΅g/g of body weight has been administered subcutaneously simultaneously with tumor cells transplantation and in 7 days. The cytotoxic activity of peritoneal macrophages has been assessed by NBT-test. The splenocyte cytotoxic activity against the LLC cells has been tested by flow cytometry. The evaluation of tumor infiltration by lymphoid cells was carried out as well. Results: TA had no significant effect on oxidative metabolism of peritoneal macrophages in tumor bearing mice. Upon TA administration, the cytotoxic activity of splenocytes against the LLC cells has been augmented in a dose-dependent manner (at the TA dose of 4 Β΅g/g, 2-fold decrease of tumor growth and metastasis has been registered) and leads to decreased tumor infiltration by mononuclear cells. Conclusion: TA caused a dose dependent inhibition of growth and metastasis of LLC. It was supposed that TA can influence the tumor grows by activation of splenocytes cytotoxic activity.Π¦Π΅Π»Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ΅ΠΉΡ
ΠΎΠ΅Π²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ Staphylococcus aureus Wood 46 (Π’Π) Π½Π° ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Ρ ΠΌΡΡΠ΅ΠΉ
Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ. ΠΠ΅ΡΠΎΠ΄Ρ: Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π°Π΅ΠΌΡΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ. Π’Π΅ΠΉΡ
ΠΎΠ΅Π²ΡΡ
ΠΊΠΈΡΠ»ΠΎΡΡ S. aureus Wood 46 ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΡΡΠΈΠ±Π°Π»ΡΠ΄Π°. ΠΠΈΡΠ»ΠΎΡΠΎΠ΄Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ²
ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π½ΠΈΡΡΠΎΡΠΈΠ½Π΅Π³ΠΎ ΡΠ΅ΡΡΠ°Π·ΠΎΠ»ΠΈΡ (ΠΠ‘Π’-ΡΠ΅ΡΡ). Π¦ΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠΎΠ² ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π’Π ΠΎΠΊΠ°Π·ΡΠ²Π°Π»Π° Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΎΡΡ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅
ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΡΡΠΈΡ. Π£ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
Π’Π Π² Π΄ΠΎΠ·Π΅ 4 ΠΌΠΊΠ³/Π³, ΡΠ°Π·ΠΌΠ΅ΡΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΡΠ»ΠΈ Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ
ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ° Π² 4 ΡΠ°Π·a ΠΌΠ΅Π½ΡΡΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ, ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ Π² Π»Π΅Π³ΠΊΠΈΡ
ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ. Π’Π Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°Π»Π°
ΠΊΠΈΡΠ»ΠΎΡΠΎΠ΄Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ². ΠΡΠΌΠ΅ΡΠ°Π»ΠΈ Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠΎΠ²: ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π’Π Π² Π΄ΠΎΠ·Π΅ 4 ΠΌΠΊΠ³/Π³ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠΎΠ² Ρ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
ΠΎΠΏΡΡΠ½ΠΎΠΉ
Π³ΡΡΠΏΠΏΡ Π² 2 ΡΠ°Π·Π° ΠΏΡΠ΅Π²ΡΡΠ°Π»Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
-Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. ΠΡΠ²ΠΎΠ΄Ρ: Π’Π ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎΠ΅
ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΎΡΡ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ², ΠΎΠΏΠΎΡΡΠ΅Π΄ΡΡΡΠΈΡ
ΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΠΎΠ΅
Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π’Π Π½Π° ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΡΠΎΡΡ, ΠΌΠΎΠΆΠ½o ΡΡΠΈΡΠ°ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΏΠ»Π΅Π½ΠΎΡΠΈΡΠΎΠ²
Antitumor and antimetastatic activities of vaccine prepared from cisplatin-resistant lewis lung carcinoma
To study antitumor and antimetastatic activities of antitumor vaccine (ATV) prepared from cisplatin (CP) sensitive and resistant strains of Lewis lung carcinoma (LLC). Methods: The inhibition of tumor growth, and the mean survival time of the tumor-bearing animals, the number and the volume of metastases were measured as the indices of ATV efficacy. The activity of cytotoxic T-lymphocytes and natural killer cells, peritoneal macrophages (Mph), the level of tumor necrosis factor and the total proteolytic activity of blood plasma (PA) were assessed. Results: ATV from CP resistant LLC prepared using cytolectin (CL) of Π. subtilis Π-7025 significantly inhibited growth of CP resistant tumors (by 52%) and increased mean survival time (MST) of animals (by 44.6%). The index of metastasis inhibition for ATV prepared from CP sensitive or resistant LLC was 154.5% and 227.0%, respectively. In all vaccine-treated animals, Mph activity was shown to be significantly increased. In spite of high antitumor and antimetastatic effects of ATV prepared from CP resistant LLC, PA in plasma of animals inoculated with CP resistant LLC was increased significantly upon vaccine administration
Elevation of efficacy of cancer vaccine combined with interferon and inducer of endogeneous interferon synthesis amixin
Aim: To study in vivo efficacy of combined administration of cancer vaccine (CV), interferon (IFN) and inducer of endogenous IFN β amixin. Materials and Methods: Sarcoma-37 cells were transplanted to female Balb/c mice. For the treatment, CV prepared from sarcoma-37 cells with the use of cytotoxic lectines from B. subtilis B-7025, murine IFN and amixin or their combinations were used. IFN production, content of circulating immune complexes and level of specific IgG antibodies in blood serum were determined by standard immunologic methods. Results: Using solid form of sarcoma-37 it has been shown that introduction of IFN and amixin significantly elevated efficacy of vaccine therapy, in particular index of tumor growth inhibition reach 89.2% and 81.7%. Upon combined use of CV and IFN or CV and amixin (25 mg/kg) respectively. Significant prolongation of average life span of the animals treated with CV and IFN or CV and amixin (25 mg/kg) has been registered (up to 92.7 Β± 10.4 and 95.0 Β± 6.2 days respectively, vs 46.8 Β± 1.5 days for control animals). Conclusion: Obtained results have shown expediency of the development of schemes for combined introduction of CV with exogenous IFN, and with inducer of endogenous IFN (amixin) for elevation of efficacy of vaccine therapy.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ (CV) Ρ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ΠΎΠΌ
(ΠΠ€Π) ΠΈ ΠΈΠ½Π΄ΡΠΊΡΠΎΡΠΎΠΌ ΡΠ½Π΄ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π β Π°ΠΌΠΈΠΊΡΠΈΠ½ΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΡΠ°ΡΠΊΠΎΠΌΡ-37 ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ
ΠΌΡΡΠ°ΠΌ-ΡΠ°ΠΌΠΊΠ°ΠΌ Balb/c. ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ CV, ΠΏΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΡΠΊΠΎΠΌΡ-37 Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΡΠΈΠ½ΠΎΠ² B. subtilis B-7025, ΠΌΡΡΠΈΠ½ΡΠΉ ΠΠ€Π (1000 Π΅Π΄.) ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½ (10 ΠΈ 25 ΠΌΠ³/ΠΊΠ³). ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Π²ΠΊΠ»ΡΡΠ°Π»ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΡΠΈΡΡΠΎΠ² ΠΠ€Π, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠΈΡ
ΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΈ ΡΡΠΎΠ²Π½Ρ
ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
IgG-Π°Π½ΡΠΈΡΠ΅Π». Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΡΠ°ΡΠΊΠΎΠΌΡ-37 ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠ€Π ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ, ΠΏΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ CV ΠΈ ΠΠ€Π ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ° (ΠΠ’Π) Π΄ΠΎΡΡΠΈΠ³Π°Π» 89,2%; ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ CV
ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½Π° (25 ΠΌΠ³/ΠΊΠ³) ΠΠ’Π ΡΠΎΡΡΠ°Π²ΠΈΠ» 81,7%. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ
ΠΆΠΈΠ·Π½ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
CV Ρ ΠΠ€Π ΠΈΠ»ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½ΠΎΠΌ (25 ΠΌΠ³/ΠΊΠ³), Π΄ΠΎ 92,7 Β± 10,4 ΠΈ 95,0 Β± 6,2 ΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠΎ
ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ°ΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΡΡΠ΅ΠΉ (46,8 Β± 1,5 ΡΡΡ, p < 0,05). ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡ
Π΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ CV ΠΊΠ°ΠΊ Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π, ΡΠ°ΠΊ ΠΈ Ρ ΠΈΠ½Π΄ΡΠΊΡΠΎΡΠΎΠΌ
ΡΠ½Π΄ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π (Π°ΠΌΠΈΠΊΡΠΈΠ½), ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Effect of the visible light irradiation of fullerene containing composites on the ros generation and the viability of tumor cells
Aim: To study the effect of fullerene-containing composites, irradiated by visible light, on the radical oxygen species (ROS) generation in thymocytes, ascitic cells from Erlichβs tumor and leukemia cells L1210; to investigate viability of these cells in the presence of fullerene-containing composites under irradiation conditions. Materials and Methods: The viability of cells was evaluated by staining with 0.4% solution of the trypan blue; ROS were detected with the use of electron paramagnetic resonance (EPR) spectroscopy and spin traps; solutions of fullerene-containing composites were irradiated with mercury-vapor lamp. Results: We demonstrated that under irradiation conditions fullerene-containing composites increase the rate of ROS generation and decrease the number of viable tumor cells. Conclusions: The obtained data allow to consider the fullerene-containing composites as potential agents for photodynamic therapy.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΡΠ»Π»Π΅ΡΠ΅Π½ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΎΠ², ΠΎΠ±Π»ΡΡΠ΅Π½Π½ΡΡ
Π²ΠΈΠ΄ΠΈΠΌΡΠΌ ΡΠ²Π΅ΡΠΎΠΌ, Π½Π° Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΡ
ΡΠΎΡΠΌ ΠΊΠΈΡΠ»ΠΎΡΠΎΠ΄Π° (Π Π€Π) Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΡΠΈΠΌΠΎΡΠΈΡΠΎΠ², Π°ΡΡΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΡΠ»ΠΈΡ
Π° ΠΈ Π»Π΅ΠΉΠΊΠΎΠ·Π° L1210. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ
ΡΡΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠΈ ΠΎΠ±Π»ΡΡΠ΅Π½Π½ΡΡ
ΡΡΠ»Π»Π΅ΡΠ΅Π½ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΎΠ². ΠΠ΅ΡΠΎΠ΄Ρ: ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ 0,4 % ΡΠ°ΡΡΠ²ΠΎΡΠ° ΡΡΠΈΠΏΠ°Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΅Π³ΠΎ; Π Π€Π ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ - ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΠΈΠΈ ΠΈ ΡΠΏΠΈΠ½ΠΎΠ²ΡΡ
Π»ΠΎΠ²ΡΡΠ΅ΠΊ;
ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΠ΅ Π²ΠΎΠ΄Π½ΡΡ
ΡΠ°cΡΠ²ΠΎΡΠΎΠ² ΡΡΠ»Π»Π΅ΡΠ΅Π½ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΎΠ² Π² Π²ΠΈΠ΄ΠΈΠΌΠΎΠΌ Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΡΡΡΠ½ΠΎΠΉ
Π»Π°ΠΌΠΏΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΡΠ»Π»Π΅ΡΠ΅Π½ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΡ ΠΏΡΠΈ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΠ²ΡΡΠ°ΡΡ ΡΠΊΠΎΡΠΎΡΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π Π€Π
ΠΈ ΡΠΌΠ΅Π½ΡΡΠ°ΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ. ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ
ΡΡΠ»Π»Π΅ΡΠ΅Π½ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΡ ΠΊΠ°ΠΊ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Π΄Π»Ρ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Experimental study of the efficacy of combined use of cancer vaccine and interferon
Aim: To study in in vivo model the efficacy of combined scheme of administration of cancer vaccine (CV) and interferon (IFN). Materials and Methods: Lewis lung carcinoma (LLC) was transplanted to male C57Bl mice. For treatment, CV prepared from LLC cells with the use of cytotoxic lectins of B. subtilis B-7025, and preparation of murine IFN-alpha were used. Therapeutic effect was evaluated by measurement of tumor volume and analysis of average life span (ALS) of treated animals. Immunologic study included determination of antitumor cytotoxicity of T-lymphocytes (CTL) and natural killer (NK) cells by radiometric method, functional activity of peritoneal macrophages (MP) β by colorimetric test with nitroazole blue, and evaluation of titers of tumor necrosis factor (TNF) and interleukins-1 and -2 (IL-1, 2). Results: It has been shown that the use of IFN preparation significantly elevated efficacy of vaccine therapy of solid form of LLC: duration of latent period of tumor growth elevated by 25%, ALS β by 28%, index of tumor growth inhibition β by 35β40%. Upon combined use of CV and IFN, significant activation of the cells β effectors of nonspecific immune defense (MP), and specific one (CTL) was observed. Conclusion: The obtained results evidence on perspectiveness of the development of combined schemes of administration of CV and IFN for elevation of the efficacy of vaccine therapy.Π¦Π΅Π»Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ (ΠΠ)
ΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π° (ΠΠ€Π). ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ (ΠΠΠ) ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΡΡΠ°ΠΌ-ΡΠ°ΠΌΡΠ°ΠΌ C57Bl.
ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΠ, ΠΏΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΠΠΠ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΡΠΈΠ½ΠΎΠ² B. subtilis B-7025,
ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΌΡΡΠΈΠ½ΠΎΠ³ΠΎ ΠΠ€Π. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠ±ΡΠ΅ΠΌΠ° ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ΅Π΄Π½Π΅ΠΉ
ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ ΠΎΠΏΡΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ°Π»ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ
ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (Π¦Π’Π) ΠΈ ΠΏΡΠΈΡΠΎΠ΄Π½ΡΡ
ΠΊΠΈΠ»Π»Π΅ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠΠ) ΡΠ°Π΄ΠΈΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ; ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (ΠΡ) Π² ΠΊΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΠ‘Π’-ΡΠ΅ΡΡΠ΅; ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΈΡΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°
ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (Π€ΠΠ), ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ²-1 ΠΈ -2. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ€Π ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΌΠΎΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΠΠΠ: Π½Π° 25% ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ
ΠΏΠ΅ΡΠΈΠΎΠ΄Π°, Π½Π° 28% β ΡΡΠ΅Π΄Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΌΡΡΠ΅ΠΉ, Π½Π° 35β40% β ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°. ΠΡΠΈ
ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΠ ΠΈ ΠΠ€Π ΠΎΡΠΌΠ΅ΡΠ°ΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ-ΡΡΡΠ΅ΠΊΡΠΎΡΠΎΠ² ΠΊΠ°ΠΊ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ
(ΠΡ), ΡΠ°ΠΊ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ (Π¦Π’Π) ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ. ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡ
Π΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΠ Ρ ΠΠ€Π, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΡ
ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Toxic effect of Cββ fullerene-doxorubicin complex towards tumor and normal cells in vitro
Creation of new nanostructures possessing high antitumor activity is an important problem of modern biotechnology. Aim. To evaluate cytotoxicity of created complex of pristine Cββ fullerene with the anthracycline antibiotic doxorubicin (Dox), as well as of free Cββ fullerene and Dox, towards different cell types β tumor, normal immunocompetent and hepatocytes. Methods. Measurement of size distribution for particles in Cββ + Dox mixture was performed by a dynamic light scattering (DLS) technique. Toxic effect of Cββ+ Dox complex in vitro towards tumor and normal cells was studied using the MTT assay. Results. DLS experiment demonstrated that the main fraction of the particles in Cββ+ Dox mixture had a diameter in the range of about 132 nm. The toxic effect of Cββ + Dox complex towards normal (lymphocytes, macrophages, hepatocytes) and tumor (Ehrlich ascites carcinoma, leukemia L1210, Lewis lung carcinoma) cells was decreased by ~10β16 % and ~7β9 %, accordingly, compared with the same effect of free Dox. Conclusions. The created Cββ + Dox composite may be considered as a new pharmacological agent that kills effectively tumor cells in vitro and simultaneously prevents a toxic effect of the free form of Dox on normal cells.Π‘ΡΠ²ΠΎΡΠ΅Π½Π½Ρ Π½ΠΎΠ²ΠΈΡ
Π½Π°Π½ΠΎΡΡΡΡΠΊΡΡΡ Π· Π²ΠΈΡΠΎΠΊΠΎΡ ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ Ρ Π²Π°ΠΆΠ»ΠΈΠ²ΠΎΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΡ ΡΡΡΠ°ΡΠ½ΠΎΡ Π±ΡΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΡΡ. ΠΠ΅ΡΠ°. ΠΡΡΠ½ΠΈΡΠΈ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΡΡΡΡ ΡΡΠ²ΠΎΡΠ΅Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΡΡΠ»Π΅ΡΠ΅Π½Ρ Cββ Π· Π°Π½ΡΠΈΠ±ΡΠΎΡΠΈΠΊΠΎΠΌ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΡΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΄Ρ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΡΡΠΈΠ½ΠΎΠΌ (ΠΠΎΠΊΡ) Π½Π° ΡΡΠ·Π½Ρ ΡΠΈΠΏΠΈ ΠΊΠ»ΡΡΠΈΠ½ (ΠΏΡΡ
Π»ΠΈΠ½Π½Ρ, ΡΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½i Ρ Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΠΈ) ΡΠ° ΠΏΠΎΡΡΠ²Π½ΡΡΠΈ ΠΎΠ΄Π΅ΡΠΆΠ°Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈ Π· ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π΄ΡΡΡ Π²ΡΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ»Π΅ΡΠ΅Π½Ρ Cββ Ρ ΠΠΎΠΊΡ Π·Π° ΡΠΌΠΎΠ² in vitro. ΠΠ΅ΡΠΎΠ΄ΠΈ. Π ΠΎΠ·ΠΏΠΎΠ΄ΡΠ» Π·Π° ΡΠΎΠ·ΠΌΡΡΠΎΠΌ ΡΠ°ΡΡΠΈΠ½ΠΎΠΊ Ρ Cββ+ ΠΠΎΠΊΡ ΡΡΠΌΡΡΡ Π²ΠΈΠΌΡΡΡΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄ΠΈΠ½Π°ΠΌΡΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ·ΡΡΡΠ²Π°Π½Π½Ρ ΡΠ²ΡΡΠ»Π° (ΠΠ Π‘). Π’ΠΎΠΊΡΠΈΡΠ½ΠΈΠΉ Π΅ΡΠ΅ΠΊΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ Cββ+ ΠΠΎΠΊΡ ΡΠΎΠ΄ΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΈΡ
Ρ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΈΡ
ΠΊΠ»ΡΡΠΈΠ½ Π²ΠΈΠ²ΡΠ°Π»ΠΈ in vitro Π· Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½ΡΠΌ ΠΠ’Π’-ΡΠ΅ΡΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΠΎ Π² ΡΡΠΌΡΡΡ Cββ+ ΠΠΎΠΊΡ Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌΡ ΡΠ΅ΡΡΡΡΡΡΡΡΡΡ ΡΠ°ΡΡΠΈΠ½ΠΊΠΈ Π· Π΄ΡΠ°ΠΌΠ΅ΡΡΠΎΠΌ 132 Π½ΠΌ. Π’ΠΎΠΊΡΠΈΡΠ½Π° Π΄ΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ Cββ+ ΠΠΎΠΊΡ ΡΠΎΠ΄ΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΈΡ
(Π»ΡΠΌΡΠΎΡΠΈΡΠΈ, ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΠΈ) Ρ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΈΡ
(Π°ΡΡΠΈΡΠ½Π° ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° ΠΡΠ»ΡΡ
Π°, Π»Π΅ΠΉΠΊΠΎΠ· L1210, ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° Π»Π΅Π³Π΅Π½Ρ ΠΡΡΡΡ) ΠΊΠ»ΡΡΠΈΠ½ Π²ΠΈΡΠ²ΠΈΠ»Π°ΡΡ ΠΌΠ΅Π½ΡΠΎΡ ΠΏΡΠΈΠ±Π»ΠΈΠ·Π½ΠΎ Π½Π° 10β16 Ρ 7β9 % Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎ ΠΏΠΎΡΡΠ²Π½ΡΠ½ΠΎ ΡΠ· Π²ΠΏΠ»ΠΈΠ²ΠΎΠΌ Π²ΡΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΠΎΠΊΡ. ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. Π ΠΎΠ·ΡΠΎΠ±Π»Π΅Π½ΠΈΠΉ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ Cββ + ΠΠΎΠΊΡ ΠΌΠΎΠΆΠ½Π° ΡΠΎΠ·Π³Π»ΡΠ΄Π°ΡΠΈ ΡΠΊ Π½ΠΎΠ²ΠΈΠΉ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, ΡΠΎ Π·Π° ΡΠΌΠΎΠ² in vitro Π·Π΄Π°ΡΠ½ΠΈΠΉ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π·Π½ΠΈΡΡΠ²Π°ΡΠΈ ΠΏΡΡ
Π»ΠΈΠ½Π½Ρ ΠΊΠ»ΡΡΠΈΠ½ΠΈ Ρ ΠΎΠ΄Π½ΠΎΡΠ°ΡΠ½ΠΎ Π·Π°ΠΏΠΎΠ±ΡΠ³Π°ΡΠΈ ΠΏΠΎΠ±ΡΡΠ½ΠΈΠΌ ΡΠΎΠΊΡΠΈΡΠ½ΠΈΠΌ Π΅ΡΠ΅ΠΊΡΠ°ΠΌ, ΠΏΡΠΈΡΠ°ΠΌΠ°Π½Π½ΠΈΠΌ ΡΡΠ°Π΄ΠΈΡΡΠΉΠ½ΠΎΠΌΡ ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΠΌΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΠΎΠΊΡ ΡΠΎΠ΄ΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΈΡ
ΠΊΠ»ΡΡΠΈΠ½.Π‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π½ΠΎΠ²ΡΡ
Π½Π°Π½ΠΎΡΡΡΡΠΊΡΡΡ Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π±ΠΈΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π¦Π΅Π»Ρ. ΠΡΠ΅Π½ΠΈΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡ ΡΠΎΠ·Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΡΡΠ»Π»Π΅ΡΠ΅Π½Π° Cββ Ρ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠΌ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΄Π° Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½ΠΎΠΌ (ΠΠΎΠΊΡ) Π½Π° ΡΠ°Π·Π½ΡΠ΅ ΡΠΈΠΏΡ ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΠ΅, Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΡ) ΠΈ ΡΡΠ°Π²Π½ΠΈΡΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Ρ ΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠ»Π»Π΅ΡΠ΅Π½Π° CββΠΈ ΠΠΎΠΊΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
in vitro. ΠΠ΅ΡΠΎΠ΄Ρ. Π Π°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎ ΡΠ°Π·ΠΌΠ΅ΡΡ ΡΠ°ΡΡΠΈΡ Π² ΡΠΌΠ΅ΡΠΈ Cββ + ΠΠΎΠΊΡ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ΅ΠΈΠ²Π°Π½ΠΈΡ ΡΠ²Π΅ΡΠ° (ΠΠ Π‘). Π’ΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° Cββ + ΠΠΎΠΊΡ Π½Π° Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠ΅ ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ in vitro ΠΈΠ·ΡΡΠ°Π»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΠ’Π’-ΡΠ΅ΡΡΠ°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² ΡΠΌΠ΅ΡΠΈ Cββ + ΠΠΎΠΊΡ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΡΡΡΡ Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌ ΡΠ°ΡΡΠΈΡΡ Ρ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 132 Π½ΠΌ. Π’ΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° Cββ+ ΠΠΎΠΊΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ (Π»ΠΈΠΌΡΠΎΡΠΈΡΡ, ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΡ) ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ (Π°ΡΡΠΈΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° ΠΡΠ»ΠΈΡ
Π°, Π»Π΅ΠΉΠΊΠΎΠ· L1210, ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ) ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ ΠΌΠ΅Π½ΡΡΠΈΠΌ Π½Π° ~ 10β16 ΠΈ 7β9 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΠΎΠΊΡ. ΠΡΠ²ΠΎΠ΄Ρ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ Cββ + ΠΠΎΠΊΡ ΠΌΠΎΠΆΠ½ΠΎ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ ΠΊΠ°ΠΊ Π½ΠΎΠ²ΡΠΉ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΠΉ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
in vitro ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΡΠ½ΠΈΡΡΠΎΠΆΠ°ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ°ΡΡ ΠΏΠΎΠ±ΠΎΡΠ½ΡΠ΅ ΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΡ, ΠΏΡΠΈΡΡΡΠΈΠ΅ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΌΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΌΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΠΎΠΊΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ
Cytotoxic activity of immune cells following administration of xenogeneic cancer vaccine in mice with melanoma B-16
Aim: To study the effects of xenogeneic cancer vaccine (XCV) developed on the basis of nervous tissue antigen from rat embryo of late gestation period and protein-containing metabolite of Bacillus subtilis with molecular weight of 70 kDa, on specific and unspecific antitumor reactions of cellular and humoral chains of immune system, and to analyze possible mechanisms of its antimetastatic action. Materials and Methods: XCV was administered triply with 3-day intervals after surgical removal of experimental melanoma Π-16 in C57Bl/6 mice. Cytotoxic activity (CTA) of splenocytes against target cells Π-562 as well as CTA of splenocytes, peritoneal macrophages (PM) and blood serum against melanoma Π-16 target cells were determined using ΠΠ’Π’ test. The content of circulating immune complexes (CIC) in blood serum was evaluated by precipitation reaction. Results: Immunologic effects of XCV vaccination in experimental animals with surgically removed melanoma B-16 in comparison with similarly treated unvaccinated mice were as follows: prevention of medium molecular weight CIC accumulation in blood serum during all observation period, significant increase (Ρ < 0.05) of CTA of effectors of unspecific antitumor immunity (natural killer cells β NK β by 25.5 Β± 1.7 vs 12.5 Β± 5.4%, and PM β by 37.3 Β± 0.6 vs 32.0 Β± 0.9%, respectively) at 37th day after the surgery, and also preservation of functional activity of specific cytotoxic lymphocytes at the level of intact control. Conclusion: The results of the study allow propose that antimetastatic effect of XCV vaccination could be based on increased CTA of NK and PM, and preservation of CTL functional activity at late terms after surgical removal of B-16 primary tumors. Key Words: xenogeneic cancer vaccine, melanoma Π-16, natural killer cells, macrophages, cytotoxic lymphocytes, cytotoxic activity, antimetastatic activity
Use of xenogeneic vaccine modified with embryonal nervous tissue antigens in the treatment of B16βmelanoma-bearing mice
The aim of the work was experimental study of anticancer efficacy of xenogeneic cancer vaccine (XCV) developed on the basis of rat embryonic nervous tissue and protein-containing metabolite of Bacillus subtilis Π-7015 (70 kDa), in Π-16 melanoma-bearing Π‘57Bl/6 mice. Methods: Immunological methods and methods of experimental oncology were used. Effects of XCV on primary and secondary organs of immune system of experimental animals, its anticancer and antimetastatic efficacy were evaluated. Results: It has been shown that XCV did not induced toxic effects on organism, and did not caused inflammatory reactions. The relation between the degree of XCV anticancer efficacy with the regimen of its use and the presence of primary tumor has been analyzed. It has been demonstrated that the developed XCV possesses significant antimetastatic activity if it is used after surgical removal of the primary tumor: in this case lung metastasis inhibition index reached 97.4%. Conclusion: High immunogenecity of new XCV creates perspectives for detailed study of its mechanisms of action. Key Words: oncofetal antigens, xenogeneic cancer vaccine, Π-16 melanoma, immunotoxicity, effectors of anticancer defence